

Patient agreement to systemic anti-cancer therapy (SACT)

Pembrolizumab with CAPOX (Capecitabine and Oxaliplatin)

Hospital/NHS Trust/NHS Board:

Responsible consultant:

Name: _____

Job title: _____

Patient details

Patient's surname/family name:

Patient's first name(s): _____

Date of birth: _____

NHS number: _____
(or other identifier)

Special requirements:
(eg other language/other communication method)

Name of proposed course of treatment (include brief explanation if medical term not clear)

- Pembrolizumab with Capecitabine and Oxaliplatin (CAPOX) for the treatment of cancer of the oesophagus OR the stomach.
- Oxaliplatin is given intravenously on day 1. Capecitabine is taken orally continuously on days 1 to 21. Each treatment cycle lasts for 21 days. Treatment is continued for up to 6 cycles.
- Pembrolizumab is intravenously or subcutaneously every three weeks **OR** every six weeks. Treatment is continued for up to 2 years, or less in the event of disease progression, unacceptable side effects or withdrawal of consent.

Where will I have treatment?

- Outpatient Day unit/case Inpatient Other: _____

Statement of health professional

(to be filled in by health professional with appropriate knowledge of proposed procedure, as specified in the hospital/Trust/NHS board's consent policy)

- Tick all relevant boxes
- I confirm the patient has capacity to give consent.
- I have explained the course of treatment and intended benefit to the patient.

The intended benefits (there are no guarantees about outcome)

- Curative – to give you the best possible chance of being cured.
- Disease control or palliative – the aim is not to cure, but to control or shrink the disease and improve both quality of life and survival.
- Adjuvant – therapy given after surgery or radiotherapy to reduce the risk of the cancer coming back.
- Neo-adjuvant – therapy given before surgery or radiotherapy to shrink the cancer, allow treatment and reduce the risk of the cancer coming back

Statement of health professional

Patient identifier/label

You may have one or more of the side effects listed

Common side effects:

Affecting more than 10 in every 100 (>10%) people

- An increased risk of getting an infection from a drop in white blood cells – it is harder to fight infections and you can become very ill.
- If you have a severe infection this can be life-threatening. Contact your doctor or hospital straight away if:**
 - **your temperature goes over 37.5°C or over 38°C, depending on the advice given by your chemotherapy team**
 - **you suddenly feel unwell (even with a normal temperature)**
- Feeling sick (nausea), being sick (vomiting), sore mouth and ulcers, diarrhoea, constipation, tummy pain, appetite loss, taste changes, dry mouth.
- Soreness, skin colour changes, peeling on palms of hands and soles of feet, skin rash, dryness, itching, hair thinning or loss.
- Tiredness and feeling weak (fatigue), headache, back pain, shortness of breath, cough.
- Allergic reactions to Oxaliplatin can be severe and happen immediately, or hours to days later.
- Anaemia (due to low red blood cells), bruising and bleeding (due to low platelets), nosebleeds, changes in how well the liver works (monitored with blood tests), changes in electrolyte levels (low calcium), high blood sugar levels – monitored with blood tests.
- Oxaliplatin may cause numbness or tingling in the hands, feet and throat (particularly in the cold) while being given or several hours after.

Occasional side effects:

Affecting between 1-10 in every 100 (1-10%) people

- Dizziness, feeling sad, difficulty sleeping.
- Build-up of fluid in the hands and feet.
- Dry mouth, indigestion, passing wind, hiccups, coughing up blood, a bleed from the back passage, a digestive tract bleed.
- Sweating, flushing, nail changes, blurred vision, sore, red, itchy eyes.
- High blood pressure.
- Changes in how well the kidneys work.
- Oxaliplatin may affect the area around the voice box which can feel difficult to swallow or breathe.
- Pain along the vein with Oxaliplatin, changes in sensation, weakness, muscle wasting, pain in the chest, bones, joints, hands and feet.

Other Pembrolizumab effects:

- This treatment acts on the immune system and can cause inflammation in parts of the body. It can cause severe side effects that can be life-threatening. It's important to treat side effects quickly to stop them getting worse. Side effects may begin during treatment, or months after.
- Commonly, inflammation of:
 - Hormone glands (thyroid, pituitary, adrenal, pancreas): high or low thyroid hormone levels, headache, tiredness, irritation, blurred or double vision, forgetfulness, high blood sugars (rarely, diabetes)
 - Stomach or intestine: tummy pain, diarrhoea, mucus or blood in the stools
 - Skin: rash, itch, colour changes, colour loss in patches (severe reactions causing blistering, peeling, sores, ulcers are less common)
 - Joints, muscles: stiffness, aches, pain, arthritis
- Occasionally, inflammation of:
 - Lungs: breathlessness, cough
 - Eyes: dry, itchy, watering eyes, pain, vision changes
 - Liver: yellowing of the skin or eyes, dark urine, tummy pain
 - Kidneys: changes in how well the kidneys work (monitored with blood tests).
- Uncommonly, inflammation of:
 - Pancreas: tummy pain, feeling or being sick
 - Brain or nerves: confusion, memory problems, seizures, numbness, tingling, weakness
 - Heart muscle: chest pain, palpitations, irregular rhythm, changes in heart function
 - Bladder: frequent or painful urination, blood in the urine
 - Rarely, the immune system may attack groups of blood cells and cause other blood conditions
- Reactions while treatment is given or a few hours after include allergic reactions, high or low blood pressure, flu-like symptoms, flushing, shortness of breath, feeling or being sick, fast or irregular heartbeat (severe reactions are less common).
- Side effects may need treatment with steroids, hormones or medicines to suppress the immune system. They may be permanent and need long-term treatment. These medicines have side effects that are sometimes severe.

Continue on to the next page

Statement of health professional

Patient identifier/label

Other risks:

- All intravenous drugs may leak out of the vein while it is being given (extravasation) and can damage the tissue around the vein. Tell the nurse straight away if you have any stinging, pain, colour changes or swelling around the vein. It's uncommon but important to deal with quickly.
- If Pembrolizumab given by injection under the skin (subcutaneously), it may cause reactions such as soreness, rash, swelling, itchiness at the injection site.
- A risk of potentially life-threatening side effects if your genetic make-up means you cannot break down Capecitabine properly (called DPD deficiency). Before you start treatment, you will have a genetic test to check for this. Tell your doctor /nurse/pharmacist straight away if you get even minor side effects.
- Rarely, severe skin reactions (Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis) causing sore red patches which blister and peel. Skin changes may follow a fever, chest infection symptoms, sensitivity of the eyes to light. Seek urgent medical advice if you have symptoms.
- Rarely, heart problems (chest pain, heart attack), stroke, lung changes, or a condition affecting blood or blood vessels causing anaemia, kidney failure, low platelets.
- Before treatment, you might have blood tests to check for viruses such as Hepatitis B, Hepatitis C, HIV or more unusual infections. This treatment may weaken your natural defence (immune) system, so infections like this could worsen or become active again if you've had them in the past. You may have medicines to prevent or treat infection.
- Effects of anti-sickness medication: constipation, diarrhoea, headaches, difficulty sleeping, agitation, indigestion.
- Steroids may cause higher blood sugar levels than usual after treatment. If you have diabetes, it may lead to higher blood sugar levels.
- Cancer and its treatment can increase your risk of developing a blood clot (thrombosis), causing pain, colour changes and swelling in an arm or leg, breathlessness, chest pain or stroke. Tell your doctor straight away if you have any symptoms.

Other risks continued:

- Changes in memory, concentration, ability to think clearly. There can be many causes of this including your treatment, diagnosis or both.
- Some anti-cancer medicines can damage ovaries and sperm leading to infertility/early menopause (hot flushes, vaginal dryness).
- Some anti-cancer medicines may damage the development of a baby in the womb. It is important not to become pregnant or make someone pregnant during treatment and for 6 months after CAPOX or 4 months after Pembrolizumab, whichever is longer. Use effective contraception.
- Complications of treatment can occasionally be life-threatening and may result in death. The risks are different for every individual. Potentially life-threatening complications include those listed on this form, but other exceedingly rare side effects may also be life-threatening.

Statement of health professional

Patient identifier/label

Any other risks and information:

-
-
- I have discussed the intended benefit and risks of the recommended treatment, and of any available alternative treatments (including no treatment).
- I have discussed the side effects of the recommended treatment, which could affect the patient straight away or in the future, and that there may be some side effects not listed because they are rare or have not yet been reported. Each patient may experience side effects differently.
- I have discussed what the treatment is likely to involve (including inpatient/outpatient treatment, timing of the treatment, blood and any additional tests, follow-up appointments etc) and location.
- I have explained to the patient, that they have the right to stop this treatment at any time and should contact the responsible consultant or team if they wish to do so.
- I have discussed concerns of particular importance to the patient in regard to treatment (please write details here): _____
-

Clinical management guideline/Protocol compliant (please tick):

- Yes No Not available If No please document reason here:
-

The following written information has been provided:

- Information leaflet for Pembrolizumab with CAPOX (Capecitabine and Oxaliplatin)
- 24 hour alert card or SACT advice service contact details
- SACT treatment record (cruk.org/treatment-record)
- Other, please state: _____
-

Health professional details:

Signed: _____

Date: _____

Name (PRINT): _____

Job title: _____

Statement of interpreter (where appropriate)

Interpreter booking reference (if applicable):

I have interpreted the information above to the patient to the best of my ability and in a way in which I believe they can understand.

Signed: _____

Date: _____

Name (PRINT): _____

Job title: _____

Statement of patient

Patient identifier/label

Please read this form carefully. If your treatment has been planned in advance, you should already have your own copy of the form which describes the benefits and risks of the proposed treatment. If not, you will be offered a copy now. If you have any further questions, do ask – we are here to help you. You have the right to change your mind at any time, including after you have signed this form.

- I have had enough time to consider my options and make a decision about treatment.
- I agree to the course of treatment described on this form.

A witness should sign below if the patient is unable to sign but has indicated their consent. A person with parental responsibility will be asked to sign for young people under the age of 16 years.

Patient's signature: _____

Name (PRINT): _____ Date: _____

Person with parental responsibility/witness' signature: _____

Name (PRINT): _____ Date: _____

Copy accepted by patient: yes / no (please circle)

Confirmation of consent

(health professional to complete when the patient attends for treatment, if the patient has signed the form in advance)

On behalf of the team treating the patient, I have confirmed that the patient has no further questions and wishes the course of treatment/procedures to go ahead.

Signed: _____

Date: _____

Name (PRINT): _____

Job title: _____

Important notes: (tick if applicable)

See also advance decision to refuse treatment

Patient has withdrawn consent (ask patient to sign and date here)

Signed: _____

Date: _____

Further information for patients

Contact details (if patient wishes to discuss options later):

Contact your hospital team if you have any questions about cancer and its treatment.

Cancer Research UK can also help answer your questions about cancer and treatment. If you want to talk in confidence, call our information nurses on freephone 0808 800 4040, Monday to Friday, 9am to 5pm. Alternatively visit cruk.org for more information.

These forms have been produced by Guy's and St. Thomas' NHS Foundation Trust as part of a national project to support clinicians in ensuring all patients are fully informed when consenting to SACT.

The project is supported by Cancer Research UK.

This does not mean you are taking part in a clinical trial.



Guidance for health professionals

(to be read in conjunction with the hospital's consent policy)

Patient identifier/label

What a consent form is for

This form documents the patient's agreement to go ahead with the treatment you have proposed. It is not a legal waiver – if patients, for example, do not receive enough information on which to base their decision, then the consent may not be valid, even though the form has been signed. Patients are also entitled to change their mind after signing the form, if they retain capacity to do so. The form should act as an aide-memoir to health professionals and patients, by providing a checklist of the kind of information patients should be offered, and by enabling the patient to have a written record of the main points discussed. In no way should the written information provided for the patient be regarded as a substitute for face-to-face discussions with the patient.

The law on consent

See the following publications for a comprehensive summary of the law on consent. Consent: Patients and doctors making decisions together, GMC 2020 (gmc-uk.org/guidance). Reference guide to consent for examination or treatment, Department of Health, 2nd edition 2009 (doh.gov.uk).

Who can give consent

Everyone aged 16 or over is presumed to have the capacity to give consent for themselves, unless the opposite is demonstrated. For young people, it is good practice to involve those with parental responsibility in the consent discussions, unless specifically asked not to. A person with parental responsibility must sign this form for a child or young person under the age of 16. Such patients should be given the opportunity to 'assent' to treatment if they wish. If a patient has the capacity to give consent but is physically unable to sign a form, you should complete this form as usual and ask an independent witness to confirm that the patient has given consent orally or non-verbally.

When NOT to use this form

If the patient lacks the capacity to give consent, you should use an alternative form available for this purpose (dependent on patient age). A patient lacks capacity if they have an impairment or disturbance of the brain, affecting the way their mind works. For example, if they cannot do one of the following:

- understand information about the decision to be made
- retain that information in their mind
- use or weigh this information as a part of their decision making process, or

- communicate their decision (by talking, using sign language or any other means)

You should always take all reasonable steps (for example involving more specialist colleagues) to support a patient in making their own decision, before concluding that they are unable to do so. Relatives cannot be asked to sign a form on behalf of an adult who lacks capacity to consent for themselves, unless they have been given the authority to do so under a Lasting Power of Attorney or as a court deputy.

Information

Information about what the treatment will involve, its benefits and risks (including side-effects and complications) and alternatives to the particular procedure proposed, is crucial for patients when making up their minds. The courts have stated that patients should be told about 'significant risks which would affect the judgement of a reasonable patient'. 'Significant' has not been legally defined, but the GMC requires doctors to tell patients about 'significant, unavoidable or frequently occurring' risks. If patients make clear they have particular concerns about certain kinds of risk, you should ensure that they are informed about these risks, even if very small or rare. You should always answer questions honestly. Sometimes, patients may make it clear that they do not want to have any information about the options, but want you to decide on their behalf. In such circumstances, you should do your best to ensure that the patient receives at least very basic information about what is proposed. Where information is refused, you should document this on the consent form or in the patient's notes.

NHS Scotland

NHS Scotland staff should refer to Healthcare Improvement Scotland. Guidance on consent for SACT and local NHS Board guidance on consent aligned to the Scottish legal framework.

References

1. Summary of Product Characteristics for individual drugs: medicines.org.uk/emc
2. Cancer Research UK: cruk.org/about-cancer/treatment/drugs
3. Macmillan Cancer Support: macmillan.org.uk/cancer-information-and-support/treatments-and-drugs
4. Guy's and St. Thomas' NHS Foundation Trust, Chemotherapy consent form